Evaluation of a Text Message-Based Approach to Depression Screening Among Cancer Survivors

Date Added
March 18th, 2025
PRO Number
Pro00142039
Researcher
Evan Graboyes

List of Studies


Keywords
Cancer, Depression
Summary

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Institution
MUSC Health Marion Medical Center
Recruitment Contact
Abigail Drake
843-670-9395
abd300@musc.edu

Evaluation of a Text Message-Based Approach to Depression Screening Among Cancer Survivors

Date Added
March 18th, 2025
PRO Number
Pro00142039
Researcher
Evan Graboyes

List of Studies


Keywords
Cancer, Depression
Summary

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Institution
MUSC Health Kershaw Medical Center
Recruitment Contact
Abigail Drake
843-670-9395
abd300@musc.edu

Evaluation of a Text Message-Based Approach to Depression Screening Among Cancer Survivors

Date Added
March 18th, 2025
PRO Number
Pro00142039
Researcher
Evan Graboyes

List of Studies


Keywords
Cancer, Depression
Summary

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Institution
MUSC Health Columbia Medical Center
Recruitment Contact
Abigail Drake
843-670-9395
abd300@musc.edu

A Multicenter Randomized Trial of EBUS-TBNA versus Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing: FROSTBITE-3

Date Added
March 18th, 2025
PRO Number
Pro00140380
Researcher
Christopher Gilbert

List of Studies

Keywords
Cancer, Lung, Pulmonary
Summary

This study is for patients scheduled for a bronchoscopy, a procedure that allows doctors to examine lungs and airways for evaluation of suspicious lung nodules. Those who give consent to participate in this study will be randomized into one of two lung biopsy sampling method groups based on the Rapid On Site Evaluation of the initial sample obtained by the doctor performing the bronchoscopy as part of the standard of care procedure for the patient. the potential groups the subject will be randomized into are: Cryoprobe or transbronchial biopsy needle. These devices are used with a bronchoscope to obtain lung tissue biopsy samples and are being evaluated to determine which is better for confirming a diagnosis. All procedures will be done via standard of care and screening will be accomplished via medical chart review. 7 days following the procedure, a member of the study team will check the subjects medical chart to assess whether any adverse events have occurred.

Institution
MUSC
Recruitment Contact
Michael Balassone
843-792-6696
Balassom@musc.edu

Telehealth-Enhanced Assessment and Management after Stroke-Blood Pressure (TEAMS-BP)

Date Added
March 12th, 2025
PRO Number
Pro00142851
Researcher
Christine Holmstedt

List of Studies


Keywords
Hypertension/ High Blood Pressure, Stroke, Stroke Recovery
Summary

The purpose of this study is to determine the best strategy to help individuals improve blood pressure control after a stroke. The study will test two different interventions (an intervention is an action taken to prevent or treat disease and/or improve health).

1) Intensive Clinic Management (ICM), which consists of clinic visits, home blood pressure monitoring, text message health reminder from CariumĀ®, a care management application, and health education.
2) Intensive Tailored Telehealth Management (ITTM), which consists of telehealth (video) visits, health coaching with lifestyle coaching company INTERVENT International, LLC, and remote blood pressure monitoring captured in CariumĀ®.

Institution
MUSC
Recruitment Contact
Caitlan LeMatty
(843) 792-8606
lemattyc@musc.edu

Drowning Risks of Patients Presenting to the Pediatric Emergency Department at MUSC's Shawn Jenkins Children's Hospital

Date Added
March 11th, 2025
PRO Number
Pro00142153
Researcher
M. Titus

List of Studies


Keywords
Pediatrics
Summary

This study is seeking to assess two known risk factors of drowning, swimming ability and water safety knowledge, in parents of children and adolescents presenting to the pediatric emergency department using questionnaires.

By collecting this data, we hope to highlight factors that contribute to disparities in drowning rates in minority racial and ethnic groups and to aid local and federal governments in developing programs that effectively combat the number one cause of unintentional injury-associated death in children ages 1-4 years. This will also provide data that may help guide pediatricians in effective anticipatory guidance for families regarding water safety. All in the effort to minimize disparities in medicine and provide more equitable care to the patients that we see.

Institution
MUSC
Recruitment Contact
M. Titus
8434753656
titusda@musc.edu

Improving needs among older adults: the ICUconnect 2 primary palliative care RCT

Date Added
March 7th, 2025
PRO Number
Pro00142688
Researcher
Dee Ford

List of Studies


Keywords
Critical Care
Summary

ICUconnect is a innovative mobile app-based primary palliative care intervention. This is a multicenter randomized controlled trial to test the intervention's efficacy in a population diverse in race, ethnicity, and geography that reflects the real-world experience of patients and family members.

Institution
MUSC
Recruitment Contact
Zerlinna Teague
(843) 792-0965
recruitment@musc.edu

A Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

Date Added
March 7th, 2025
PRO Number
Pro00140123
Researcher
Lara Wine Lee

List of Studies


Keywords
Skin
Summary

This study aims to evaluate the effectiveness of ruxolitinib cream compared to a placebo (vehicle) cream in treating vitiligo in children aged 2 to 12 years. The vehicle cream looks identical to the ruxolitinib cream but contains no active medication. By comparing these two treatments, researchers hope to determine whether ruxolitinib is more effective than the placebo in improving facial and body vitiligo symptoms. This study could provide important insights into new treatment options for young children affected by this condition.

Institution
MUSC
Recruitment Contact
Kennedy McLeod
843-792-4091
mcleodke@musc.edu

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for low Tumor Burden Follicular Lymphoma

Date Added
March 6th, 2025
PRO Number
Pro00142136
Researcher
Brian Hess

List of Studies


Keywords
Cancer, Cancer/Lymphoma, Drug Studies, Men's Health, Women's Health
Summary

This study is for subjects diagnosed with follicular lymphoma. The purpose of this study is to assess if treatment with Mosunetuzumab can improve long term remission in patients with low tumor burden follicular lymphoma compared to rituximab. The treatment period for the Rituximab arm is approximately 40 weeks. The treatment period for the Mosunetuzumab arm is approximately 24 weeks. However the subject may remain in the study for up to 10 years for the follow-up period.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Characterization of B-cells and wearing off phenomena in diverse populations following initiation of ublituximab

Date Added
March 4th, 2025
PRO Number
Pro00140830
Researcher
Andrew Keegan

List of Studies

Keywords
Multiple Sclerosis
Summary

The purpose of this study is to understand differences in responses to those beginning treatment with ublituximab (Briumvi) as prescribed for Multiple Sclerosis by their treating provider. The study consists of three visits where some questions are asked about experience with Multiple Sclerosis and blood samples are drawn for genetic research and immune cell counts. While taking part in this study, some of the possible risks include those related to having blood drawn, risk of loss of confidentiality and risks related to genetic research.

Institution
MUSC
Recruitment Contact
Alison Line
843-792-2845
line@musc.edu



-- OR --